Actively Recruiting
Phase 3 Study Comparing CGT9486 Plus Sunitinib Versus Sunitinib Alone for Advanced or Metastatic Gastrointestinal Stromal Tumors
Led by Cogent Biosciences, Inc. · Updated on 2026-06-16
482
Participants Needed
126
Research Sites
222 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
CONDITIONS
Brief Title
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Research Team
C
Cogent Biosciences
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
